The 2026 European Association of Urology (EAU) annual meeting featured an advancement in metastatic castration resistant ...

The 2026 European Association of Urology (EAU) annual meeting featured an advancing prognostics and therapeutics in ...

The median overall survival was 38.21 months with radium-223 plus enzalutamide and 32.62 months with enzalutamide alone. For patients with metastatic castration-resistant prostate cancer (mCRPC) with ...

The median OS was 28 months with abiraterone-prednisone, 37 months with olaparib alone, and 68 months with abiraterone-prednisone-olaparib. In patients with metastatic castration-resistant prostate ...

Pharmacokinetic analysis revealed sustained activity at 15 days, a finding corroborated by imaging that demonstrated prolonged tumor retention of the therapeutic agent. Importantly, researchers found ...

Real-world PRECISION data in 500 taxane-naïve, PSMA-positive mCRPC patients showed median PFS 13.5 months (95% CI, 11.7–14.7), aligning with PSMAfore efficacy expectations. Earlier sequencing mattered ...

A new research paper was published in Volume 13 of Oncoscience on February 7, 2026, titled “Reduced immunogenicity of MYC amplified, metastatic prostate cancer.” ...

Final phase 3 EORTC 1333/PEACE-3 data show enzalutamide plus radium-223 extends OS and radiographic progression-free survival in mCRPC with bone metastases. Final data from the phase 3 EORTC ...

The market for radioligand therapies is expected to grow significantly in the coming years. This is due to the increasing number of patients who are ...

J&J JNJ announced that the European Commission has approved its precision therapy, Akeega (niraparib and abiraterone acetate dual action tablet), for expanded use in prostate cancer. The regulatory ...

Bayer today announced results from the ongoing global Phase I first-in-human, dose-escalation PAnTHa study (NCT06217822) evaluating the safety, tolerability and preliminary efficacy of ...

In a second EU approval today, Johnson & Johnson got a green light for Akeega (niraparib and abiraterone acetate) for the ...